Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events | MicrobiomeTrials← Back to trialsNCT05038254
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
RecruitingNAINTERVENTIONAL
Start: 2021-05-12Est. Completion: 2028-01-31
Enrollment target: 750 participants Locations- M D Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Esophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of car…
Anchorage, United StatesCompleted Dec 31, 2026
Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Esophageal AdenocarcinomaMetastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Esophageal AdenocarcinomaUnresectable Gastric AdenocarcinomaUnresectable Gastroesophageal Junction Adenocarcinoma
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to pacli…
Little Rock, United StatesEst. completion Oct 31, 2027